Fifty-Two Weeks, Open Label Extension Trial to Evaluate Safety and Efficacy of Org 50081 in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 176001 or 176002
Phase of Trial: Phase III
Latest Information Update: 08 Oct 2018
At a glance
- Drugs Esmirtazapine (Primary)
- Indications Insomnia
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 20 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jan 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 09 Oct 2009 Schering-Plough added as trial sponsor and affiliate as reported by ClinicalTrials.gov.